A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease

Trial Profile

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; PGG-glucan (Primary)
  • Indications Advanced breast cancer; Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IMPRIME-1
  • Sponsors Biothera
  • Most Recent Events

    • 22 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2017 According to a Biothera Pharmaceuticals media release, trial design will be presented at the 2017 ASCO Annual Meeting.
    • 23 Feb 2017 According to a Biothera media release, patient dosing has been initiated in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top